{"id":"placebo-plus-chemoradiotherapy","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Nausea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"50-70%","effect":"Hair loss"}]},"_chembl":{"chemblId":"CHEMBL780","moleculeType":"Small molecule","molecularWeight":"393.35"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Chemoradiotherapy involves the use of chemotherapy and radiation to kill cancer cells. The placebo serves as a control group in clinical trials, allowing researchers to compare the effectiveness of the treatment.","oneSentence":"This drug works by combining a placebo with chemoradiotherapy to treat cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:18.649Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic cancer"}]},"trialDetails":[{"nctId":"NCT01386385","phase":"PHASE1, PHASE2","title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma","enrollment":53},{"nctId":"NCT07225621","phase":"PHASE2","title":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Alpheus Medical, Inc.","startDate":"2026-01-28","conditions":"Glioblastoma, GBM","enrollment":103},{"nctId":"NCT07458529","phase":"PHASE2","title":"Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Seventh Medical Center of PLA General Hospital","startDate":"2026-02-10","conditions":"Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy","enrollment":50},{"nctId":"NCT07454720","phase":"PHASE2, PHASE3","title":"A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"Locally Advanced Resectable Rectal Cancer","enrollment":165},{"nctId":"NCT07010263","phase":"PHASE3","title":"A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-06-13","conditions":"Small Cell Lung Cancer","enrollment":560},{"nctId":"NCT06992427","phase":"PHASE3","title":"High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-06-05","conditions":"Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8","enrollment":228},{"nctId":"NCT03706690","phase":"PHASE3","title":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-11-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":407},{"nctId":"NCT06079671","phase":"PHASE3","title":"Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-22","conditions":"Locally Advanced Cervical Cancer","enrollment":800},{"nctId":"NCT03521154","phase":"PHASE3","title":"A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-07-19","conditions":"Non Small Cell Lung Cancer (Stage III)","enrollment":216},{"nctId":"NCT06117774","phase":"PHASE3","title":"Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-02-20","conditions":"Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer","enrollment":400},{"nctId":"NCT05211895","phase":"PHASE3","title":"A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-02-18","conditions":"Non-Small Cell Lung Cancer","enrollment":860},{"nctId":"NCT04221945","phase":"PHASE3","title":"Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-12","conditions":"Uterine Cervical Neoplasms","enrollment":1060},{"nctId":"NCT03040999","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-04-05","conditions":"Head and Neck Neoplasms","enrollment":804},{"nctId":"NCT06532279","phase":"PHASE2","title":"Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2024-12-16","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":98},{"nctId":"NCT04550260","phase":"PHASE3","title":"Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-10-19","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":640},{"nctId":"NCT05221840","phase":"PHASE3","title":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-02-07","conditions":"Non-Small Cell Lung Cancer","enrollment":1051},{"nctId":"NCT04543617","phase":"PHASE3","title":"A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-28","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":760},{"nctId":"NCT05353257","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-05-17","conditions":"Limited-Stage Small Cell Lung Cancer","enrollment":511},{"nctId":"NCT07324018","phase":"PHASE2","title":"Spirulina Derivative for Radiation Esophagitis","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-01-12","conditions":"Radiation-induced Esophagitis","enrollment":70},{"nctId":"NCT07317609","phase":"PHASE1","title":"Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-07-15","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":60},{"nctId":"NCT04227509","phase":"PHASE2","title":"Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2020-06-04","conditions":"Nasopharyngeal Carcinoma","enrollment":53},{"nctId":"NCT06964815","phase":"NA","title":"Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients","status":"RECRUITING","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2025-11-12","conditions":"Glioblastoma, IDH Wild-type and STAT3-positive Glioblastoma","enrollment":110},{"nctId":"NCT03703297","phase":"PHASE3","title":"Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-09-27","conditions":"Small Cell Lung Cancer","enrollment":730},{"nctId":"NCT04250922","phase":"PHASE2, PHASE3","title":"LAM561 With RT and TMZ for Adults With Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Laminar Pharmaceuticals","startDate":"2019-12-01","conditions":"Primary Glioblastoma, Glioblastoma Multiforme","enrollment":144},{"nctId":"NCT07235306","phase":"PHASE2","title":"Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-12-01","conditions":"NSCLC Stage III, Ensartinib, Chemoradiotherapy","enrollment":45},{"nctId":"NCT07168200","phase":"PHASE3","title":"A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","startDate":"2025-10-17","conditions":"Advanced Cervical Cancer","enrollment":720},{"nctId":"NCT03519971","phase":"PHASE3","title":"Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-29","conditions":"Non-Small Cell Lung Cancer","enrollment":328},{"nctId":"NCT04459715","phase":"PHASE3","title":"A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2020-08-07","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":730},{"nctId":"NCT07189572","phase":"PHASE3","title":"Intranasal Corticosteroid Spray for Preventing Otitis Media With Effusion After Radiotherapy in Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-10","conditions":"Otitis Media, Otitis Media With Effusion After Nasopharyngeal Carcinoma, Radiotherapy Side Effects","enrollment":168},{"nctId":"NCT06256588","phase":"PHASE3","title":"A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-03-21","conditions":"Neoplasms, Head and Neck","enrollment":864},{"nctId":"NCT04380636","phase":"PHASE3","title":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-06","conditions":"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":870},{"nctId":"NCT04624204","phase":"PHASE3","title":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-08","conditions":"Small Cell Lung Cancer","enrollment":672},{"nctId":"NCT07042711","phase":"NA","title":"Impact of Vitamin D on Therapeutic Respons in NPC Chemoradiated Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Indonesia University","startDate":"2025-01-10","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":300},{"nctId":"NCT07035626","phase":"PHASE1, PHASE2","title":"A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-06-25","conditions":"Radiation-induced Xerostomia","enrollment":58},{"nctId":"NCT01720563","phase":"PHASE2","title":"A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy","status":"TERMINATED","sponsor":"PhytoHealth Corporation","startDate":"2012-12","conditions":"Cancer-related Fatigue","enrollment":17},{"nctId":"NCT03957590","phase":"PHASE3","title":"A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-06-12","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":370},{"nctId":"NCT05508347","phase":"PHASE2","title":"Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2022-04-20","conditions":"Nasopharyngeal Carcinoma","enrollment":170},{"nctId":"NCT06712888","phase":"PHASE3","title":"Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-02-17","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":466},{"nctId":"NCT06851819","phase":"PHASE2","title":"Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-03-01","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":64},{"nctId":"NCT06789796","phase":"PHASE3","title":"a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-02","conditions":"Small-cell Lung Cancer","enrollment":636},{"nctId":"NCT04241185","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-19","conditions":"Urinary Bladder Neoplasms","enrollment":520},{"nctId":"NCT04210115","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)","enrollment":703},{"nctId":"NCT06569459","phase":"PHASE2","title":"Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-07-09","conditions":"Esophageal Cancer","enrollment":60},{"nctId":"NCT05235516","phase":"PHASE3","title":"A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-06-21","conditions":"Locally Advanced Cervical Carcinoma","enrollment":636},{"nctId":"NCT03830866","phase":"PHASE3","title":"Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-02-15","conditions":"Locally Advanced Cervical Cancer","enrollment":770},{"nctId":"NCT01657734","phase":"","title":"Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2011-09","conditions":"Malignant Gliomas","enrollment":30},{"nctId":"NCT06095583","phase":"PHASE3","title":"Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-11-15","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC)","enrollment":756},{"nctId":"NCT04600817","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"TJ Biopharma Co., Ltd.","startDate":"2020-12-31","conditions":"Newly Diagnosed Glioblastoma","enrollment":160},{"nctId":"NCT02546102","phase":"PHASE3","title":"Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma","status":"SUSPENDED","sponsor":"Precision Life Sciences Group","startDate":"2024-12","conditions":"Glioblastoma Multiforme","enrollment":234},{"nctId":"NCT06333821","phase":"PHASE3","title":"A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2024-04-01","conditions":"Cervical Cancer","enrollment":460},{"nctId":"NCT03840902","phase":"PHASE2","title":"M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-04-16","conditions":"Non-small Cell Lung Cancer","enrollment":153},{"nctId":"NCT03689712","phase":"PHASE3","title":"ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients","status":"COMPLETED","sponsor":"Galera Therapeutics, Inc.","startDate":"2018-10-03","conditions":"Oral Mucositis","enrollment":455},{"nctId":"NCT04308785","phase":"PHASE2","title":"A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-12-01","conditions":"Carcinoma, Small Cell Lung","enrollment":24},{"nctId":"NCT01711658","phase":"PHASE2","title":"TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2013-03-15","conditions":"Non-HPV Locally Advanced Head and Neck Cancer","enrollment":142},{"nctId":"NCT02125461","phase":"PHASE3","title":"A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-07","conditions":"Non-Small Cell Lung Cancer","enrollment":713},{"nctId":"NCT06048926","phase":"NA","title":"Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT05451576","phase":"NA","title":"Sodium Selenite Supplementation in Patients With Head and Neck Cancer","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2020-08-12","conditions":"Head and Neck Squamous Cell Carcinoma, Selenium, Sodium Selenite","enrollment":60},{"nctId":"NCT05623267","phase":"PHASE2, PHASE3","title":"Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-01","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":346},{"nctId":"NCT03925090","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-12-08","conditions":"Nasopharyngeal Carcinoma","enrollment":150},{"nctId":"NCT01824823","phase":"PHASE2","title":"Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2014-06-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":3},{"nctId":"NCT03728556","phase":"PHASE3","title":"A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"CStone Pharmaceuticals","startDate":"2018-10-26","conditions":"Non-Small Cell Lung Cancer Stage III","enrollment":381},{"nctId":"NCT01711541","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-10-22","conditions":"Head and Neck Squamous Cell Carcinoma, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Oropharyngeal Carcinoma AJCC v7","enrollment":24},{"nctId":"NCT04648020","phase":"PHASE2, PHASE3","title":"Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.","status":"TERMINATED","sponsor":"Monopar Therapeutics","startDate":"2021-02-11","conditions":"Chemoradiotherapy-Induced Severe Oral Mucositis","enrollment":190},{"nctId":"NCT02573324","phase":"PHASE3","title":"A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-01-04","conditions":"Glioblastoma, Gliosarcoma","enrollment":691},{"nctId":"NCT05842746","phase":"PHASE2","title":"Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-05","conditions":"Glioblastoma, IDH-wildtype","enrollment":74},{"nctId":"NCT02853604","phase":"PHASE3","title":"Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer","status":"TERMINATED","sponsor":"Advaxis, Inc.","startDate":"2015-12-15","conditions":"High Risk Cervical Cancer, Advanced Cervical Cancer","enrollment":110},{"nctId":"NCT05736315","phase":"NA","title":"Use of a Fermented Dairy Beverage in Cervical Cancer Patients Undergoing Concurrent Chemoradiation Therapy","status":"COMPLETED","sponsor":"National Institute of Cancerología","startDate":"2005-04-25","conditions":"Cervical Cancer, Stage IIB","enrollment":42},{"nctId":"NCT03237325","phase":"PHASE3","title":"DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer","status":"COMPLETED","sponsor":"Soligenix","startDate":"2017-12-04","conditions":"Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral Mucositis","enrollment":266},{"nctId":"NCT01062425","phase":"PHASE2","title":"Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-02-26","conditions":"Adult Glioblastoma, Adult Gliosarcoma","enrollment":261},{"nctId":"NCT04951635","phase":"PHASE3","title":"A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2021-03-18","conditions":"Non-small Cell Lung Cancer","enrollment":150},{"nctId":"NCT03476018","phase":"PHASE3","title":"Trial to Optimally Show the Pharmacological Action of Z-100","status":"COMPLETED","sponsor":"Zeria Pharmaceutical","startDate":"2018-04-02","conditions":"Cervical Cancer","enrollment":72},{"nctId":"NCT05351931","phase":"NA","title":"Role of Antisecretory Factor in Curative Radiochemotherapy for Anal Carcinoma","status":"UNKNOWN","sponsor":"Uppsala University Hospital","startDate":"2022-06","conditions":"Anal Cancer","enrollment":38},{"nctId":"NCT04325763","phase":"PHASE3","title":"A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-05-27","conditions":"Stage III Non-small-cell Lung Cancer","enrollment":315},{"nctId":"NCT02085460","phase":"PHASE2","title":"A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2014-03","conditions":"Head and Neck Cancer","enrollment":94},{"nctId":"NCT05079438","phase":"PHASE3","title":"Dendrobium Huoshanense Suppository in Rectal Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-09-07","conditions":"Locally Advanced Rectal Cancer","enrollment":168},{"nctId":"NCT02952586","phase":"PHASE3","title":"Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-11-28","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":697},{"nctId":"NCT04426955","phase":"PHASE3","title":"Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-06-30","conditions":"Esophageal Cancer","enrollment":396},{"nctId":"NCT05032027","phase":"NA","title":"Oral Probiotics on Radiation Enteritis Stage Ⅱ Induced by Pelvic Concurrent Chemoradiotherapy","status":"UNKNOWN","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2021-08-27","conditions":"Pelvic Cancer, Enteritis, Probiotics,Chemoradiotherapy","enrollment":40},{"nctId":"NCT05023863","phase":"PHASE2, PHASE3","title":"The Effect of Alpha Lipoic Acid on the Incidence and Severity of Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2021-09-01","conditions":"Radiation-Induced Mucositis","enrollment":70},{"nctId":"NCT02768558","phase":"PHASE3","title":"Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC","status":"TERMINATED","sponsor":"RTOG Foundation, Inc.","startDate":"2016-10-17","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT03673735","phase":"PHASE3","title":"Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC","status":"WITHDRAWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2021-06","conditions":"Squamous Cell Head and Neck Carcinoma","enrollment":""},{"nctId":"NCT04861467","phase":"PHASE2","title":"Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-06-01","conditions":"HNSCC","enrollment":155},{"nctId":"NCT03170115","phase":"PHASE2","title":"Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer","status":"TERMINATED","sponsor":"Instituto Nacional de Cancer, Brazil","startDate":"2017-11-30","conditions":"Rectal Cancer, Adenocarcinoma, Locally Advanced Malignant Neoplasm, Chemoradiation","enrollment":25},{"nctId":"NCT03234465","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day","status":"TERMINATED","sponsor":"Oragenics, Inc.","startDate":"2017-07-18","conditions":"Oral Mucositis","enrollment":200},{"nctId":"NCT04632342","phase":"PHASE2","title":"Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients","status":"UNKNOWN","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2020-11","conditions":"Radiation Pneumonitis, Lung Cancer","enrollment":87},{"nctId":"NCT01149642","phase":"NA","title":"Randomised Study of Mucositis Prevention After Radiochemotherapy Treatment for Head and Neck Cancer","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2009-11","conditions":"Severe Acute Mucositis, Head and Neck Cancer","enrollment":160},{"nctId":"NCT02412371","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"AbbVie","startDate":"2015-04-30","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":48},{"nctId":"NCT01636934","phase":"PHASE2","title":"Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-07","conditions":"Lung Cancer","enrollment":51},{"nctId":"NCT03745222","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Celgene","startDate":"2019-05-22","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":1},{"nctId":"NCT04203511","phase":"PHASE3","title":"INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)","status":"WITHDRAWN","sponsor":"Incyte Corporation","startDate":"2020-07-31","conditions":"Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT04404491","phase":"PHASE3","title":"Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2020-06-01","conditions":"Esophageal Malignant Neoplasm, Local Recurrence","enrollment":240},{"nctId":"NCT04394598","phase":"PHASE2","title":"A Study of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-03-01","conditions":"Locally Advanced Rectal Cancer","enrollment":210},{"nctId":"NCT02452463","phase":"PHASE2","title":"Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2015-06-29","conditions":"Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis, Stage II Lung Non-Small Cell Cancer AJCC v7","enrollment":8},{"nctId":"NCT00955942","phase":"PHASE1","title":"Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy","status":"TERMINATED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2007-12","conditions":"Lung Cancer, Radiation Toxicity","enrollment":48},{"nctId":"NCT04244708","phase":"PHASE2, PHASE3","title":"The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-02-10","conditions":"Pituitary Adenomas","enrollment":150},{"nctId":"NCT02520453","phase":"PHASE2","title":"Adjuvant Durvalumab for Esophageal Cancer","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2016-02","conditions":"Esophageal Cancer","enrollment":86},{"nctId":"NCT02721563","phase":"PHASE4","title":"A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC","status":"COMPLETED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2016-02-25","conditions":"Esophageal Neoplasms","enrollment":77},{"nctId":"NCT00153803","phase":"PHASE3","title":"Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2005-05","conditions":"Carcinoma, Non-Small-Cell Lung, Non-small Cell Lung Cancer, NSCLC","enrollment":245},{"nctId":"NCT00884741","phase":"PHASE3","title":"Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-04-15","conditions":"Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma","enrollment":637},{"nctId":"NCT02123511","phase":"PHASE2","title":"Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-04","conditions":"Mucositis, Oral Complications, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"placebo plus chemoradiotherapy","genericName":"placebo plus chemoradiotherapy","companyName":"Biotech Pharmaceutical Co., Ltd.","companyId":"biotech-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug works by combining a placebo with chemoradiotherapy to treat cancer. Used for Metastatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}